SCM
RCUS icon

Soleus Capital Management’s Arcus Biosciences RCUS Stock Holding History

Soleus Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.76M Sell
451,983
-260,000
-37% -$5.62M 0.4% 51
2025
Q4 		$17M Buy
+711,983
New +$14.5M 0.63% 43

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Soleus Capital Management's RCUS Position: Q1 2026 in Review

Soleus Capital Management reduced its Arcus Biosciences (RCUS) stake by 37% in Q1 2026, selling an estimated $5.62M and leaving 451,983 shares worth $9.76M. The position accounts for 0.4% of the portfolio, ranked #51.

Soleus Capital Management first reported a position in RCUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $17M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Soleus Capital Management held 451,983 shares of Arcus Biosciences worth $9.76M as of Q1 2026.
  • Soleus Capital Management sold 260,000 Arcus Biosciences shares in Q1 2026, an estimated $5.62M.
  • Arcus Biosciences made up 0.4% of Soleus Capital Management's portfolio in Q1 2026, its #51 holding.
  • Soleus Capital Management first reported a position in Arcus Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Soleus Capital Management's Arcus Biosciences position peaked at $17M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.